Two-faced leukemia?

Leukemia results when normal immune cells accumulate mutations that drive uncontrolled growth. T cell acute lymphoblastic leukemia (T-ALL) derives from immature T cells, whereas acute myeloid leukemia (AML) comes from myeloid cells.

Only 50% of adult T-ALL patients can be cured, and a team led by Adolfo Ferrando at Columbia University Institute for Cancer Genetics is trying to understand why.

Ferrando's group examined the genes expressed in tumors from T-ALL patients and found that half of the tumors expressed some genes normally found in stem cells and AML tumors. Many of these AML-like T-ALL tumors contained specific AML-associated mutations, and one quarter had mutations in ETV6, a gene involved in stem cell function—cells whose self-renewing capacity can propagate cancers. Additional work is needed to understand whether mutations in ETV6 influence the prognosis of patients with tumors in the gray zone between T-ALL and AML.

More information: Van Vlierberghe, P., et al. 2011. J. Exp. Med. doi:10.1084/jem.20112239

Journal reference: Journal of Experimental Medicine

Provided by Rockefeller University